SYDNEY--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released an in-depth report, Bladder Cancer – Global Clinical Trial Landscape 2024, offering key insights for stakeholders across the oncology and clinical research sectors..

悉尼--（商业新闻短讯）--全球全方位服务临床合同研究组织（CRO）Novotech与生物技术公司合作，在每个阶段加速开发先进和新颖的治疗方法，该组织发布了一份深入的报告《膀胱癌-2024年全球临床试验格局》，为肿瘤学和临床研究部门的利益相关者提供了重要见解。。

Bladder cancer remains a significant health challenge worldwide, with over 614,000 new cases and 220,600 deaths recorded in 2022. Novotech’s latest report provides a detailed examination of the evolving landscape in bladder cancer research, with a focus on clinical trial trends, emerging therapeutic strategies, and regional variations in patient outcomes..

膀胱癌仍然是全世界面临的重大健康挑战，2022年有超过614000例新病例和220600例死亡记录。Novotech的最新报告详细研究了膀胱癌研究的发展趋势，重点是临床试验趋势，新兴治疗策略以及患者预后的区域差异。。

Key Highlights from the Report:

报告的主要亮点：

Bladder Cancer Statistics: A thorough analysis of incidence and survival data, highlighting that Europe and Asia account for the majority of global cases.

膀胱癌统计：对发病率和生存数据的彻底分析，强调欧洲和亚洲占全球病例的大多数。

Clinical Trial Landscape: An overview of over 1,500 bladder cancer clinical trials initiated since 2019, with North America, Asia-Pacific, and Europe leading in trial volume.

临床试验概况：自2019年以来启动的1500多项膀胱癌临床试验概述，北美，亚太地区和欧洲的试验量领先。

Advancements in Treatment: Exploration of innovative therapies, including immunotherapy, targeted treatments, and combination therapies, which are opening new avenues in bladder cancer care.

治疗进展：探索创新疗法，包括免疫疗法，靶向治疗和联合疗法，这为膀胱癌护理开辟了新途径。

Future Projections: Bladder cancer cases are projected to exceed 1.2 million annually by 2050, underscoring the urgent need for advanced treatment options and accessible healthcare solutions.

未来预测：预计到2050年，膀胱癌病例每年将超过120万，这突显出迫切需要先进的治疗方案和可获得的医疗保健解决方案。

This report explores valuable information for biotech professionals, oncologists, researchers and scientists. By examining trial density, recruitment efficiencies, and regional disparities in treatment outcomes, the report provides actionable insights for those aiming to enhance the efficiency and effectiveness of bladder cancer trials..

本报告为生物技术专业人员、肿瘤学家、研究人员和科学家探索了有价值的信息。通过检查试验密度，招募效率和治疗结果的地区差异，该报告为旨在提高膀胱癌试验效率和有效性的人提供了可行的见解。。

Download the Full Report

下载完整报告

To access the full report and gain a deeper understanding of the trends shaping bladder cancer research, download the report here.

要访问完整的报告并更深入地了解影响膀胱癌研究的趋势，请在此处下载报告。

About Novotech Novotech-CRO.com

关于Novotech Novotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Novotech成立于1997年，是一家全球全方位服务的临床合同研究组织（CRO），专注于与生物技术公司合作，以加速各个阶段先进和新颖疗法的开发。

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006..

Novotech因其行业领先的贡献而备受赞誉，它获得了众多久负盛名的奖项，包括Frost&Sullivan 2024年全球生物技术首席执行官年度奖、临床试验领域卓越奖2024年、2024年雇主选择奖、2024年美国工作大典、2024年布兰登·霍尔金奖、2023年首席执行官领导力奖、2023年亚太细胞与基因治疗临床试验卓越奖、2006年以来的亚太合同研究组织年度公司奖。。

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice..

该公司提供一整套服务，包括实验室、一期设施、药物开发咨询、监管专业知识，并拥有5000多个临床项目的经验，包括一期至四期临床试验和生物等效性研究。Novotech在全球34个办公地点拥有分支机构，拥有3000多名专业团队，是值得信赖的端到端战略合作伙伴。。

For more information or to speak to an expert team member visit www.Novotech-CRO.com

欲了解更多信息或与专家团队成员交谈，请访问www.Novotech-CRO.com